OTC : AAVXF
Abivax S.A. (AAVXF)Healthcare : BiotechnologyYou need sign in
$80,03
-58.97 (-42.42%) today
Abivax S.A., a French biopharmaceutical firm, specializes in the discovery and enhancement of pharmaceutical treatments targeting inflammatory conditions, infectious illnesses, and various forms of cancer. The company's flagship compound, ABX464, is currently undergoing Phase IIb clinical evaluations for ulcerative colitis, Crohn's disease, and COVID-19. It is also being assessed in Phase IIa trials for rheumatoid arthritis, and has successfully concluded Phase IIa studies demonstrating viral remission in individuals with HIV. Additionally, Abivax is advancing ABX 196, an investigational immune-enhancing agent, through Phase 1/2 clinical trials for its potential application in treating hepatocellular carcinoma. Further research initiatives by the company explore therapies for Dengue fever, influenza, and respiratory syncytial virus. Abivax S.A. holds licensing agreements with prominent French research institutions, including the French National Centre for Scientific Research, the University of Montpellier, and the Institut Curie. Established in 2013, the company maintains its primary offices in Paris, France.
- Website:
- https://www.abivax.com
- CEO:
- Marc de Garidel
- Country:
- FR
- Full-time employees:
- 69
- Address:
- 7-11 Boulevard Haussmann, Paris, IF, 75009
- IPO date:
- Sep 27, 2016
Open
$139,00
High
$139,00
Low
$80,03
Mkt. cap
5.88B
Avg. vol.
342.00
Volume
500.00
52-wk high
$139,00
52-wk low
$71,26
Shares outstanding
73.43M
No stock-specific news available.
Latest reported earnings
Q1 2026
Report date: May 22, 2026
EPS / Est.
$-0.705 / $-0.927
+24.01% beat
Revenue / Est.
$1.50M / $396.40K
+278.90% beat
Past earnings
| Fiscal period | Report date | EPS / Est. | Revenue / Est. |
|---|---|---|---|
| Q4 2025 | Mar 23, 2026 | $-1.233 / $-1.363 (+9.53% beat) | $516.78K / $1.82M (-71.59% miss) |
| Q3 2025 | Dec 15, 2025 | $-2.464 / $-0.796 (-209.64% miss) | $2.40M / $1.36M (+76.02% beat) |
| Q2 2025 | Sep 8, 2025 | $-0.993 / $-0.937 (-6.08% miss) | $1.35M / $1.40M (-3.97% miss) |
| Q4 2024 | Mar 24, 2025 | $-1.553 / $-1.509 (-2.92% miss) | $5.89M / $2.69M (+118.80% beat) |
| Q3 2024 | Nov 14, 2024 | $-1.398 / $-1.471 (+4.99% beat) | $7.30M / $3.59M (+103.05% beat) |
| Q2 2024 | Sep 9, 2024 | $-1.392 / $-1.471 (+5.34% beat) | $7.11M / $3.69M (+92.94% beat) |
| Q1 2024 | Apr 2, 2024 | $-1.978 / $-0.938 (-110.85% miss) | $2.55M / $2.54M (+0.37% beat) |
| Q2 2023 | Sep 21, 2023 | $-1.582 / - (n/a) | $2.45M / - (n/a) |
| Q3 2022 | Dec 31, 2022 | $-1.946 / $-1.884 (-3.32% miss) | $2.42M / - (n/a) |
| Q2 2022 | Sep 15, 2022 | $-1.841 / - (n/a) | $2.33M / - (n/a) |
| Q4 2021 | Mar 16, 2022 | $-1.678 / - (n/a) | - / - (n/a) |
| Q2 2021 | Sep 23, 2021 | $-1.341 / - (n/a) | - / - (n/a) |
Marc de Garidel - CEO
Didier Blondel - EVP, CFO & Board Secretary
James Berger - Global Head of Marketing
Ida Hatoum - Chief People & Compliance Officer
Hema Keshava - Senior Vice President of Finance
Marc de Garidel - Chief Executive Officer & Director
Mary Mantock - Senior VP & Global Head of Regulatory Affairs
Patrick Malloy - Senior VP & Head of Investor Relations
Kevin Shan - Vice President & Global Head of Biometrics
Jerome Denis - Executive Vice President of Process Development & Manufacturing
Pierre Courteille - Chief Business Officer
Chris Rabbat - Vice President & Global Head of Medical Affairs